Abstract 5699
Background
TNBC accounts for approximately 15% to 20% of breast cancers. Patients with TNBC tend to have a worse prognosis and are typically diagnosed at a younger age compared with patients with other breast cancer subtypes. Chemotherapy has been the foundation of care for patients with mTNBC, but new targeted treatment (tx) options are now available (olaparib, veliparib, atezolizumab). The IMpassion130 study showed that the combination of atezolizumab + nab-paclitaxel (pac) improved efficacy outcomes in 1L mTNBC. This analysis was conducted to assess the characteristics of patients receiving taxanes in current US clinical practice.
Methods
A total of 2250 female patients newly diagnosed with mTNBC and who received 1L tx between 2005 and 2015 were identified in the Truven MarketScan database. Descriptive statistics were used to summarize baseline characteristics. Multivariate logistic regression models were used to identify independent predictors of treatment choice. Models included all prognostic variables.
Results
The median age of patients at 1L tx for mTNBC was 58 years. Most patients lived in metropolitan areas (86%) and were covered by commercial health insurance (74%). Taxane-containing regimens accounted for 54% of all 1L tx, with 23% receiving monotherapy and 26% receiving combination. nab-Pac was most commonly given as a single agent (64%), whereas pac and docetaxel were more commonly given in combination with other agents (62% and 67%, respectively). Single-agent vs combination taxane use, as well as the use of nab-pac regimens (vs docetaxel or pac) increased after 2010 compared with prior to 2010. Patients enrolled in a health maintenance organization plan were less likely to receive nab-pac than pac (odds ratio [OR], 0.41 [0.21-0.79]) or docetaxel (OR, 0.25 [0.12-0.51]). Other factors, such as comorbidities and number of metastatic sites, were not clearly associated with any specific taxane monotherapy tx.
Conclusions
Taxanes were the most common tx choice for 1L mTNBC. Patient characteristics were similar among patients who received pac and nab-pac monotherapy, suggesting that they are prescribed interchangeably when reimbursed by insurance.
Clinical trial identification
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Chris Lum, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
J. O’Shaughnessy: Honoraria (self): AbbVie Inc.; Honoraria (self): Agendia; Honoraria (self): Amgen Biotechnology; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Eisai; Honoraria (self): Genentech; Honoraria (self): Genomic Health; Honoraria (self): GRAIL; Honoraria (self): Immunomedics; Honoraria (self): Heron Therapeautics; Honoraria (self): Ipsen Biopharmaceuticals; Honoraria (self): Jounce Therapeutics; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Myriad; Honoraria (self): Novartis; Honoraria (self): Ondonate Therapeutics; Honoraria (self): Pfizer; Honoraria (self): Puma Biotechnology; Honoraria (self): Seattle Genetics; Honoraria (self): Syndax Pharmaceuticals. L.A. Emens: Officer / Board of Directors: Society for Immunotherapy of Cancer (SITC); Honoraria (self): Abbvie; Honoraria (self): Amgen; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self): Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Honoraria (self): Gritstone; Honoraria (self): Medimmune; Honoraria (institution), Travel / Accommodation / Expenses: Macrogenics; Non-remunerated activity/ies, No Compensation: eTHeRNA; Travel / Accommodation / Expenses: Novartis; Honoraria (self): Peregrine; Honoraria (self), Travel / Accommodation / Expenses: Replimune; Honoraria (self): Syndax; Honoraria (self): Vaccinex; Research grant / Funding (institution): Aduro Biotech; Research grant / Funding (institution): Breast Cancer Research Foundation; Research grant / Funding (institution): Corvus; Research grant / Funding (institution): Department of Defense; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): HeritX, Inc.; Research grant / Funding (institution): Maxcyte; Honoraria (self), Travel / Accommodation / Expenses: Bristol Meyers Squibb; Research grant / Funding (institution): Merck; Licensing / Royalties, IND Licensing/vaccine <25K: Aduro. S. Chui: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. K. Russell: Full / Part-time employment: F. Hoffmann-La Roche, Ltd. S. Lin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. C. Flores Avile: Full / Part-time employment: Genesis Research. P. Luhn: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. A. Schneeweiss: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Molecular Partner; Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Novartis; Honoraria (self): MSD; Honoraria (self): Tesaro; Honoraria (self): Lilly.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract